Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
The purpose of this study is to determine the efficacy of modafinil with regard to reducing cancer-related fatigue in cancer patients following chemotherapy or radiation therapy. Secondarily, the effect of modafinil on cognitive dysfunction in the same population will be assessed.
The researchers hypothesize that administering modafinil (PROVIGIL®) to patients experiencing fatigue following completion of cancer treatment will lead to reduction in patient fatigue and prevention of or improvement in patient cognitive dysfunction.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fatigue is a very common and troublesome side effect experienced in cancer patients before, during and after chemotherapy and radiation treatment. This protocol will increase knowledge about the occurrence and treatment of fatigue that develops during cancer treatments with the rationale that:
- better control of the fatigue reported by patients during and following cancer treatment is needed,
- there are few systematic data on the etiology of fatigue following cancer treatment, and
- there is evidence indicating that chemotherapy is associated with cognitive dysfunction.
Comparisons: In this randomized, placebo-controlled study of cancer patients following their chemotherapy or radiation therapy, we will assess the efficacy of modafinil for relieving cancer-related fatigue by actigraphy and for preventing or improving cognitive dysfunction by computer-generated tasks that have previously been utilized to examine drug-induced changes in performance (CDR Cognitive Assessment). Additional outcome measures will include the Fatigue Symptom Checklist, POMS, Fatigue Severity Scale, sleepiness measured by the Epworth Sleepiness Scale, cytokine blood levels, depression measured by the CES-D, and psychological adjustment to cancer measured by the Mini-MAC.
The primary objective is to:
- compare changes in patient reported fatigue following completion of chemotherapy and/or radiation treatment for cancer in patients who receive open-label modafinil (PROVIGIL®) for 4 weeks
Secondary objectives are to:
- assess the persistence of any effect found with a randomized trial of responders to modafinil or placebo for 4 weeks (responders are those who report at least a 1 point decrease in fatigue as measured by the Brief Fatigue Inventory)
- assess the degree to which modafinil can prevent or reduce cognitive dysfunction following treatment for cancer
- investigate potential relationships among depression, fatigue, cytokines, and cognitive dysfunction
Anticipated results could provide potentially important new information with regard to clinical, theoretical, and methodologic applications; that is, improved pharmacologic and perhaps behavioral control of the debilitating fatigue commonly experienced by patients undergoing treatment for cancer.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester, James P. Wilmot Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is longer than one-month post chemotherapy and/or radiation treatment for an initial diagnosis of cancer
- Patient is 18 years of age or older
- Patient is able to swallow medication
- Patient has a Brief Fatigue Inventory (BFI) question #3 "fatigue worst" score of 2 or greater
Exclusion Criteria:
- Patient has ever taken modafinil (PROVIGIL)
- Patient has taken an anticonvulsant for a seizure disorder; has taken any of the following on a regular basis within the past 30 days, a psychostimulant (e.g., amphetamines, methylphenidate [Ritalin], pemoline [Cylert]), or a monoamine oxidase inhibitor (MAOIs)
- Patient has a history of clinically significant cardiac disease, uncontrolled hypertension, alcohol or drug abuse, severe headaches, glaucoma, seizure disorder, narcolepsy, a psychotic disorder, or Tourette's syndrome
Patient presently taking on a regular basis:
- an anticoagulant (Coumadin [warfarin], heparin); note that low dose Coumadin (1 mg by mouth daily) given for maintenance of venous access devices is acceptable
- alpha-interferon or interleukin-2,
- a corticosteroid (dexamethasone, prednisone, prednisolone)
- Patient has a narrowing (pathological or iatrogenic) or obstruction of the gastrointestinal tract
- Patient is currently pregnant or nursing (if currently using a steroidal contraceptive for fertility control, participant must agree to use a barrier method of contraception during the study and for one full menstrual cycle following the study
- Patient has uncontrolled anemia; receiving treatment for anemia and currently stable is acceptable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Modafinil
Modafinil 200 mg taken by mouth once a day.
Subjects will take 2 100 mg tablets each morning.
|
|
|
Placebo Comparator: placebo
Inactive sugar pill, 2 are taken once a day in the morning
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
degree to which modafinil can reduce patient fatigue following treatment for cancer
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
cytokine blood levels
|
|
depression measured by the Center for Epidemiologic Studies-Depression scale (CES-D)
|
|
cognitive function measured by the Cognitive Drug Research (CDR) Cognitive Assessment
|
|
psychological adjustment to cancer measured by the Mini-Mental Adjustment to Cancer scale (Mini-MAC)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gary R. Morrow, Ph.D., M.S., University of Rochester, James P. Wilmot Cancer Center, Radiation Oncology Department, Behavioral Medicine Unit, Box 704, 601 Elmwood Avenue, Rochester, NY 14642
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- U2702
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.